ELOX (Eloxx Pharmaceuticals) EBIT: $-4.95 Mil (TTM As of Dec. 2025)

What is Eloxx Pharmaceuticals EBIT?

Eloxx Pharmaceuticals ELOX +5.57% 17 EBIT is $-4.95 Mil as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Eloxx Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-4.95 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eloxx Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 was -39.28%. Eloxx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eloxx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -13.15%.

Eloxx Pharmaceuticals (NAS:ELOX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eloxx Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-6.438 * ( 1 - 0% )	/	( (19.962	+	12.816)	/ 2 )
=	-6.438	/	16.389
=	-39.28 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.976	-	7.349	-	( 0.111	-	max(0, 27.311	-	2.976	+	0.111	))
=	19.962

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.27	-	4.361	-	( 4.785	-	max(0, 17.177	-	5.27	+	4.785	))
=	12.816

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Eloxx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.946	/	( ( (0 + max(-18.285, 0))	+	(0 + max(-15.692, 0)) )	/	2 )
=	-4.946	/	( ( 0	+	0 )	/	2 )
=	-4.946	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.359	+	0	+	0.147)	-	(7.349	+	13.347	+	0.094999999999999)
=	-18.285

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.485)	-	(4.361	+	11.816	+	0)
=	-15.692

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eloxx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-4.946	/	37.605
	=	-13.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals EBIT Related Terms

Eloxx Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's EBIT can be seen below:

Eloxx Pharmaceuticals EBIT Chart

Eloxx Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-65.47

-34.12

-15.90

-2.00

-4.95

Eloxx Pharmaceuticals Semi-Annual Data
	Jun06	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
EBIT	Get a 7-Day Free Trial															-65.47	-34.12	-15.90	-2.00	-4.95

ELOX vs CPMV, OGEN, CASIF: EBIT Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eloxx Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

17GF Score

Eloxx Pharmaceuticals Inc ELOX

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Eloxx Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.95 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-4.95 Mil mean?

Eloxx Pharmaceuticals (ELOX) has a EBIT of $-4.95 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eloxx Pharmaceuticals.

Is Eloxx Pharmaceuticals' EBIT too high?

Eloxx Pharmaceuticals' current EBIT is $-4.95 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.

How does Eloxx Pharmaceuticals' EBIT compare to CPMV and OGEN?

Eloxx Pharmaceuticals' EBIT of $-4.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eloxx Pharmaceuticals. Eloxx Pharmaceuticals's current EBIT is $-4.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Eloxx Pharmaceuticals stock overvalued right now?

Eloxx Pharmaceuticals (ELOX) has a current EBIT of $-4.95 Mil. The current EBIT is $-4.95 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current EBIT is $-4.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CPMV OGEN CASIF VBIO JAGX BBLG PKTX SLXN CLDI CMND VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476

Website https://www.eloxxpharma.com

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

17GF Score

Get the complete analysis for ELOX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05

Price

View ELOX Analysis

See EBIT data for all stocks →